MX2022016587A - Bioconjugado tetravalente de shigella (shigella4v). - Google Patents
Bioconjugado tetravalente de shigella (shigella4v).Info
- Publication number
- MX2022016587A MX2022016587A MX2022016587A MX2022016587A MX2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A
- Authority
- MX
- Mexico
- Prior art keywords
- shigella
- tetravalent
- shigella4v
- bioconjugate
- bioconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040844P | 2020-06-18 | 2020-06-18 | |
| US202063043883P | 2020-06-25 | 2020-06-25 | |
| EP20182139 | 2020-06-25 | ||
| EP20182138 | 2020-06-25 | ||
| PCT/IB2021/055361 WO2021255684A1 (en) | 2020-06-18 | 2021-06-17 | Shigella-tetravalent (shigella4v) bioconjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016587A true MX2022016587A (es) | 2023-02-01 |
Family
ID=76502778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016587A MX2022016587A (es) | 2020-06-18 | 2021-06-17 | Bioconjugado tetravalente de shigella (shigella4v). |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230346902A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4168040A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023530154A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697396A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024294A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3185719A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016587A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021255684A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026087718A1 (en) * | 2024-10-23 | 2026-04-30 | Institut Pasteur | A multivalent shigella vaccine and methods of making and using thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| ES2535084T3 (es) | 2005-05-11 | 2015-05-05 | Eth Zurich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| US9238830B2 (en) | 2006-12-13 | 2016-01-19 | The Governors Of The University Of Alberta | Methods and systems for O-glycosylating proteins |
| SI2257307T1 (sl) | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| CN101569744A (zh) * | 2009-01-20 | 2009-11-04 | 张鑫 | 一种细菌性痢疾多价疫苗 |
| NO2501406T3 (cg-RX-API-DMAC7.html) | 2009-11-19 | 2018-05-19 | ||
| KR20150068998A (ko) * | 2012-10-12 | 2015-06-22 | 글리코박신 아게 | 숙주 세포 변형 방법 |
| EP2917351B1 (en) * | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| NZ723328A (en) | 2014-02-24 | 2018-01-26 | Glycovaxyn Ag | Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture |
| CN106659799B (zh) * | 2014-07-25 | 2020-07-17 | 碧奥辛斯有限责任公司 | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| CN114796472A (zh) * | 2015-06-16 | 2022-07-29 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
-
2021
- 2021-06-17 CA CA3185719A patent/CA3185719A1/en active Pending
- 2021-06-17 WO PCT/IB2021/055361 patent/WO2021255684A1/en not_active Ceased
- 2021-06-17 EP EP21733220.4A patent/EP4168040A1/en active Pending
- 2021-06-17 MX MX2022016587A patent/MX2022016587A/es unknown
- 2021-06-17 US US18/001,551 patent/US20230346902A1/en active Pending
- 2021-06-17 CN CN202180043251.6A patent/CN115697396A/zh active Pending
- 2021-06-17 BR BR112022024294A patent/BR112022024294A2/pt unknown
- 2021-06-17 JP JP2022577503A patent/JP2023530154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4168040A1 (en) | 2023-04-26 |
| WO2021255684A1 (en) | 2021-12-23 |
| BR112022024294A2 (pt) | 2023-02-28 |
| CN115697396A (zh) | 2023-02-03 |
| CA3185719A1 (en) | 2021-12-23 |
| US20230346902A1 (en) | 2023-11-02 |
| JP2023530154A (ja) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023553205A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| GEP20247633B (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
| GEAP202316334A (en) | Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines | |
| EP4656208A3 (en) | Methods for making polysaccharide-protein conjugates | |
| PL411824A1 (pl) | Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 | |
| EA035991B9 (ru) | Новый полисахарид и его применения | |
| MY182282A (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| MX2022005452A (es) | Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2. | |
| MX2019013605A (es) | Material botanico homogeneizado que comprende un modificador de ph basico. | |
| AR118389A1 (es) | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización | |
| NO20005672L (no) | Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet | |
| CY1115710T1 (el) | Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης | |
| MX2021014710A (es) | Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo. | |
| MX2022015734A (es) | Proteinas de exotoxina a modificadas. | |
| TR200200065T2 (tr) | Dış salgılama bozukluklarının tedavisi için terkip | |
| BG107220A (en) | Antitumoral ecteinascudin derivatives | |
| ZA202101663B (en) | Purified capsular polysaccharides of streptococcus pneumoniae | |
| MX2024008039A (es) | Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos. | |
| NO20026242L (no) | Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse | |
| AR105010A1 (es) | Composiciones inmunógenas | |
| CL2023000740A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas. | |
| MX2022014249A (es) | Composición farmacéutica para tratar el cáncer. | |
| MX2023013665A (es) | Polipeptidos del sars-cov-2. | |
| AU9385501A (en) | Vectors for molecule delivery to cd11b expressing cells | |
| MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. |